Skip to main content

Advertisement

SpringerLink
Log in

Bladder cancer

Multi-omic profiling refines the molecular view

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease for which treatment has, historically, lagged behind that of other solid tumour types. A more detailed understanding of the biology of individual tumours, and the identification of molecular features providing prognostic and predictive information is key to the application of personalized care for patients with MIBC. The publication of a study of 412 samples now provides such data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: mRNA expression-based subtypes of muscle-invasive bladder cancer according to The Cancer Genome Atlas.

References

  1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).

    Article  Google Scholar 

  2. Abdollah, F. et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 37, 219–225 (2013).

    Article  Google Scholar 

  3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

  4. Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540–556.e25 (2017).

    Article  CAS  Google Scholar 

  5. Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).

    Article  CAS  Google Scholar 

  6. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).

    Article  CAS  Google Scholar 

  7. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).

    Article  CAS  Google Scholar 

  8. Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152–165 (2014).

    Article  CAS  Google Scholar 

  9. Sjodahl, G. et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113–125 (2017).

    Article  Google Scholar 

  10. Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544–554 (2017).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Work in the authors' laboratory is supported by a programme grant from Yorkshire Cancer Research (LPA376).

Author information

Authors and Affiliations

  1. Carolyn D. Hurst and Margaret A. Knowles are at the Leeds Institute of Cancer and Pathology, St James's University Hospital, Beckett Street, University of Leeds, Leeds LS9 7TF, UK.,

    Carolyn D. Hurst & Margaret A. Knowles

Authors
  1. Carolyn D. Hurst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret A. Knowles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret A. Knowles.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hurst, C., Knowles, M. Multi-omic profiling refines the molecular view. Nat Rev Clin Oncol 15, 203–204 (2018). https://doi.org/10.1038/nrclinonc.2017.195

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.195

  • Springer Nature Limited

This article is cited by

Search

Navigation